Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: New and useful markers for pre-eclampsia?

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 146, Issue 1, 2009, Pages 46-49

  Rousseau, Aurélie ^a   Favier, Rémi ^b   Van Dreden, Patrick ^a  

^a PAE Parispace 3   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Pre eclampsia; Procoagulant phospholipids; Thrombomodulin activity; Tissue factor activity

Indexed keywords

PHOSPHOLIPID; PROCOAGULANT; THROMBOMODULIN; THROMBOPLASTIN;

ADULT; ARTICLE; BLOOD VESSEL INJURY; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM INJURY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 68349125534     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2009.06.001     Document Type: Article

References (27)

1. Franchini M. Haemostasis and pregnancy. Thromb Haemost 95 (2006) 401-413
2. Perry K.G., and Martin Jr. J.N. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin Obstet Gynecol 35 (1992) 338-350
3. Redman C.W., and Sargent I.L. Latest advances in understanding preeclampsia. Science 308 (2005) 1592-1594
4. Parry G.C., and Mackman N. Mouse embryogenesis requires the tissue factor extracellular domain but not cytoplasmic domain. J Clin Invest 105 (2000) 1547-1554
5. Uszynski M., Zekanowska E., Uszynski W., and Kuczynski J. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic and blood plasma: implications for the mechanism of amniotic fluid embolism. Eur J Obstet Gynecol 95 (2001) 163-166
6. Isermann B., Sood R., Pawlinski R., et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 9 (2003) 331-337
7. Gu J.M., Crawley J.T.B., Ferrell G., et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem 227 (2002) 43335-43343
8. Kurosawa S., Stearns-Kurosawa D.J., Hidari N., and Esmon C.T. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 100 (1997) 411-418
9. Silveira A., Schatteman K., Goossens F., et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84 (2000) 364-368
10. van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
11. Ohlin A.K., Larsson K., and Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 3 (2005) 976-982
12. Boffa M.C. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker. Haemostasis 26 Suppl 4 (1996) 233-243
13. Knight M., Redman C.W., Linton E.A., and Sargent I.L. Shedding syncytiotrophoblast microvilli into the maternal circulation in preeclampsia pregnancies. Br J Obstet Gynaecol 105 (1998) 632-640
14. Freyssinet J.M. Cellular microparticles: what are they bad or good for?. Thromb Haemost 1 (2003) 1655-1662
15. Van Wijk M.J., Nieuwland R., Boer K., et al. Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction?. Am J Obstet Gynecol 178 (2002) 450-456
16. Freeman D.J., Tham K., Brown E.A., Rumley A., Lowe G.D., and Greer I.A. Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia. J Thromb Haemost 6 (2008) 421-427
17. Lok C.A., Van Der Post J.A., Sargent I.L., et al. Changes in microparticle numbers and cellular origin during pregnancy and preeclampsia. Hypertens Pregnancy 27 (2008) 344-360
18. National High Blood Education Program Working Group. Report on high blood pressure in pregnancy. Am J Obstet Gynecol 183 (2002) S1-S22
19. Tanjung M.T., Siddik H.D., Hariman H., and Koh S.C.L. Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb/Hemost 11 4 (2005) 467-473
20. Wallenburg H.C.S. Changes in the coagulation and platelets in pregnancy-induced hypertension and preeclampsia. In: Sharp F., and Symonds E.M. (Eds). Hypertension in Pregnancy (1987), Perinatology Press, Ithaca, NY 227
21. Lanir N., Aharon A., and Brenner B. Procoagulant and anticoagulant mechanisms in human placental. Semin Thromb Hemost 29 (2003) 175-183
22. Pedersen B., Holscher T., Sato Y., Pawlinski R., and Mackman N. A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 105 (2005) 2777-2782
23. Chabloz P., Reber G., Boehlen F., Hohlfeld P., and De Moerloose P. TAFI antigen and d-dimer levels during normal pregnancy and at delivery. Br J Haematol 115 (2001) 150-152
24. Schjetlein R., Haugen G., and Wisloff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Circulation 96 (1997) 569-574
25. Antovic J.P., Hamad R.R., Antovic A., Blomback M., and Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb Haemost 88 (2002) 644-647
26. Chetaille P., Alessi M.C., Kouassi D., Morange P.E., and Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 83 (2000) 902
27. Bretelle F., Sabatier F., Desprez D., et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 89 (2003) 486-492